Biogen (NASDAQ:BIIB) announces new positive data from its long-term NURTURE study evaluating Spinraza (nusinersen) in presymptomatic patients with spinal muscular atrophy (SMA).
At data cutoff in February which includes almost
an additional year of follow-up, all treated patients (n=25; median age:
3.8 years) were alive and remained permanent ventilation-free. All
children who have been able to walk independently have maintained their
ability to do so.
No new safety signals have been reported.
The open-label study has been extended for another three years.
Related ticker: Ionis Pharmaceuticals (NASDAQ:IONS)
https://seekingalpha.com/news/3581849-biogens-spinraza-shows-sustained-benefit-in-presymptomatic-sma-patients
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.